Microbix Presenting STI Multiplex Test Controls at AACC
Retrieved on:
Tuesday, July 26, 2022
Goal, TSX, Association, Diagnosis, STI, Vertically transmitted infection, GLOBE, Genital ulcer, Treponema pallidum, U.S. FDA, QAP, Laboratory, TGA, ISO 9001, Herpes simplex virus, Health, American Association, Health Canada, Ulcer, QAP (Colombia), News, Organization, CE, American Association for Clinical Chemistry, GUD, AACC, Company, FDA, Poster, Engineering, Antigen, Medical device, OTCQX, Vaccine, Treponema
GUDs are a current and growing global health concern, with over 20 million new cases each year.
Key Points:
- GUDs are a current and growing global health concern, with over 20 million new cases each year.
- Microbix has overcome challenges in formulation and appears to be the first to develop a multiplex whole-workflow control for GUD assays.
- Microbix creates proprietary biological products for human health, with over 100 skilled employees and sales approaching C$ 2.0 million per month.
- Microbix is ISO 9001 and 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides CE marked products.